Navigation Links
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy,of BF-200 ALA In Actinic Keratosis

age in Germany has actinic keratosis, the incidence doubles every 10 years. We will develop the 10 % formulation further for the treatment of this unusually frequent disease and intend to bring it to registration by 2009," commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG.

About Biofrontera AG Biofrontera AG is specialized in the development of pharmaceutical products in the area of dermatology. The company is characterized by a broad, relatively close to the market product portfolio and a solid liquidity. Biofrontera is listed in the regulated market of the Düsseldorf stock exchange under the symbol B8F and the ISIN number DE0006046113. http://www.biofrontera.com/

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.

For further information please contact:

Anke zur Mühlen Corporate Communication

+ 49 (0) 214 87632 22 + 49 (0) 214 87632 90 a.zurmuehlen@biofrontera.com

Biofrontera AG Hemmelrather Weg 201 D- 51377 Leverkusen, Germany


'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... -- , La fórmula de leche ... tolerancia a la proteína de leche de vaca  ... leche de la vaca (APLV) es la principal alergia alimentaria ... APLV se trataba eliminando las proteínas lácteas de ... posible adquirir tolerancia oral en un número significativo ...
(Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced plans ... ) on the clinical development of Nile,s proprietary natriuretic ... disease applications. "We are very pleased to ...
... Feb. 28, 2011 PAREXEL International Corporation (Nasdaq: ... presenting at the Raymond James Investors Conference in Orlando, FL. ... be making a presentation on PAREXEL at 2:50 p.m.  ET ... of this presentation will be available through the "Investors" ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3PAREXEL International to Present at Raymond James Investors Conference 2
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
(Date:10/27/2014)... discarding microscopic warning signs about your health. , But a ... "going to waste." , Brigham Young University chemist Adam Woolley ... of kidney disease and prostate cancer in a few minutes. ... a tiny tube and see how far it goes. , ... will latch onto disease markers and nothing else. Urine from ...
(Date:10/27/2014)... a new therapy by watching others use it, Surprisingly ... New technology is like an influential colleague -- opinionated ... every five to seven days , CHICAGO --- ... they are persuaded to do so by an influential colleague, ... innovations also have relevance for business, education and research. ...
(Date:10/27/2014)... 27, 2014 Jiwa Law Corporation now ... are involved in motor vehicle accidents. The corporation now ... and rehabilitation expenses up to a maximum of $150,000. ... or chiropractor treatments, medications, home support services, and medical ... huge impact on the way you live your life,” ...
(Date:10/27/2014)... -- For children with broken bones, ibuprofen is ... researchers report. Although both medications are ... injuries, oral morphine carries more risk for negative ... that orally administered morphine and other [narcotic painkillers] ... evidence for the oral administration of morphine in ...
Breaking Medicine News(10 mins):Health News:New insights into the development of ciliopathies 2Health News:Prostate cancer, kidney disease detected in urine samples on the spot 2Health News:Persuading doctors to quickly adopt new treatments 2Health News:Persuading doctors to quickly adopt new treatments 3Health News:Jiwa Law Corporation Now Assists Clients With ICBC Claims for Motor Vehicle Accidents 2Health News:For a Child's Fracture, Use Ibuprofen, Not Morphine: Study 2
... problem often leading to diabetes and cardiovascular disease. Being ... // resistant, but not all overweight or obese people ... insulin resistance, however, it is too difficult to administer ... have come up with a simple way to identify ...
... new study was conducted by the Johns Hopkins Bloomberg School ... 55 and older. Researchers used magnetic resonance imaging// to determine ... changes in the brain correlated with the risk of stroke ... moderate alcohol consumption and a decrease in brain size of ...
... surgery, according to a new study done by researchers ... //results are due to medical or psychosocial factors. ... surgery than men. Most have attributed this to the fact ... and have fewer social supports. In this study, investigators from ...
... drugs that lower cholesterol levels, research shows they remain ... a patient is in the hospital or at a ... Foundation looked at the relationship between when lipid-lowering therapy ... outpatient setting and its long-term use. ,For the ...
... major complication of diabetes, despite the fact most are ... performed among the diabetic population. ,Researchers studied ... of about 900 diabetic patients who had been diagnosed ... for 20 years to assess how these microvascular changes ...
... may improve strength and mobility in patients with osteoarthritis.// ... osteoarthritis who were older than age 50. Patients were divided ... week in a swimming pool, the second exercised in a ... the water and gym programs focused on resistance exercises. ...
Cached Medicine News:
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish....
Solid lower plate with outside width 28 mm. Open upper plate. Serrated handle with locking thumb screw and polished finish. Right....
Medicine Products: